June 17, 2020 – Renowned author and veteran pharmacist, James J. Rybacki is pleased to announce the release of his new book, Essential Guide to Prescription Drugs on Remdesivir. Remdesivir is a Covid-19 experimental drug recently approved for emergency use by the FDA. The latest eBook from James J. Rybacki gives more than 40 categories of information from benefits to risks, to how the medicine works, what to do when taking the drug, and a whole lot of other important information.
The Essential Guide to Prescription Drugs on Remdesivir zeros in on research and SMART dosing instructions. This new eBook even includes essential topics to discuss with your doctor, such as possible adverse effects, and other important developments to watch out for while taking the drug, and also herbal medicines, and drug interactions to avoid.
“I am glad to contribute my best in the fight against the Covid-19 pandemic that has changed our lives, crumbled a once-thriving economy, and further placed vulnerable people in a more dangerous situation than they ever imagined. My new book is a complete guide for everyone looking to know what to expect from Remdesivir, how it can help them fight against Covid-19 and the risks involved as well,” says Dr. Rybacki.
He says further, “The Essential Guide to Prescription Drugs on Remdesivir is available for everyone as an Ebook and printed book, and I strongly recommend that everyone get a copy. As the author of Essential Guide to Prescription Drugs series, I have firsthand experience on how following instructions such as those laid out in my new book can save lives, especially at a time like this when the whole world is faced with a pandemic.”
As the world battles the Covid-19 pandemic, Remdesivir is one of the most tested and trusted drugs approved for emergency use. However, most people lack proper guidance and information on the risks and benefits involved in using Remdevisir.
About The Author
James J. Rybacki, Pharm.D., is a trusted voice with over three decades of hospital and clinical experience that include major academic medical center leadership at UTSW in Dallas, Texas as well as National Cardiology organization leadership in the Professional Education Committee of the American Heart Association. Dr. Rybacki received the Early Lifetime Achievement award from the University of Nebraska College of Pharmacy in 2007.
Media Contact:
The Medicine Information InstituteContact Person: James J. Rybacki Email: [email protected] Phone number to book interviews: 410.310.2578
Available NOW from IngramSparks & Ebook stores World wide
Ebook: ISBN: 978-1-891678-77-6
Print: ISBN: 978-1-891678-78-3
Author Website: www.EssentialGuideToPrescriptionDrugs.com
Media ContactCompany Name: Med ConsultContact Person: James J. Rybacki, Pharm.D.Email: Send EmailPhone: 410.310.2578Country: United StatesWebsite: https://www.essentialguidetoprescriptiondrugs.com/
